![](/img/cover-not-exists.png)
Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience
Soubrier, Martin, Pereira, Bruno, Frayssac, Thomas, Fan, Angelique, Couderc, Marion, Malochet-Guinamand, Sandrine, Mathieu, Sylvain, Tatar, Zuzana, Tournadre, Anne, Dubost, Jean-JacquesLanguage:
english
Journal:
International Journal of Rheumatic Diseases
DOI:
10.1111/1756-185X.13156
Date:
September, 2017
File:
PDF, 197 KB
english, 2017